Viruses 2014, 6(3), 1395-1409; doi:10.3390/v6031395
Gene Therapy Targeting HIV Entry
1
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
2
Department of Pathology, Children's Hospital of Philadelphia, 34th and Civic Center Blvd-5th Floor Main Building, Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Received: 4 November 2013 / Revised: 19 February 2014 / Accepted: 26 February 2014 / Published: 21 March 2014
(This article belongs to the Special Issue Gene Therapy for Retroviral Infections)
View Full-Text
|
Download PDF [565 KB, uploaded 12 May 2015]
Abstract
Despite the unquestionable success of antiretroviral therapy (ART) in the treatment of HIV infection, the cost, need for daily adherence, and HIV-associated morbidities that persist despite ART all underscore the need to develop a cure for HIV. The cure achieved following an allogeneic hematopoietic stem cell transplant (HSCT) using HIV-resistant cells, and more recently, the report of short-term but sustained, ART-free control of HIV replication following allogeneic HSCT, using HIV susceptible cells, have served to both reignite interest in HIV cure research, and suggest potential mechanisms for a cure. In this review, we highlight some of the obstacles facing HIV cure research today, and explore the roles of gene therapy targeting HIV entry, and allogeneic stem cell transplantation in the development of strategies to cure HIV infection. View Full-TextKeywords:
HIV; gene therapy; HIV cure; HIV entry; HIV reservoir; CCR5 delta 32
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Scifeed alert for new publications
Never miss any articles matching your research from any publisher- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
